Crimson Life Sciences is the only translations practice
that is exclusively, 100% dedicated to the requirements
of the medical device industry.
Crimson awarded world's first patent for
labeling translation risk management.
Crimson is the first translation practice to hold ISO 9001,
ISO 13485, and ISO 14971 certifications.
Crimson's risk management process helped
one client save over $360,000 and cut labeling
turnaround times by 50%.
Crimson's ISO 14971-registered risk management
system improved accuracy rates by 36%, while
reducing service costs by 20%.
Crimson joins Translations.com and TransPerfect to
create EnCompass Content Solutions for medical
device manufacturers.

Content Solutions for Device Makers

Every content management service and technology you need, from start-up to global enterprise, including process automation, content re-use, and e-content delivery.
read more >

U.S. Patent No. 8,140,322 B2 Labeling Translation Risk Management

Crimson holds the world's only patent for device labeling translation. Crimson's patent advances “state of the art” and helps satisfy critical risk management requirements.
read more >

Crimson Life Sciences


Founded in 1992, Crimson is the only translation practice devoted to Class II and III devices and Class B, C, and D IVDs. Thanks to our exclusive dedication to the medical device industry, we understand the important patient safety and risk management function of translated labeling. Built on over 20 years of experience, we also deliver fluent, technically accurate translations of device marketing and training materials.

Expert Opinion


$400 million potential savings for the device industry with advanced content management technology.

Research & Resources


Login for original and third-party research and resources
read more >